- Home
- MNMD vs EYPT Comparison
MNMD vs EYPT Comparison
Compare MNMD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- EYPT
- Stock Information
- Founded
- MNMD 2019
- EYPT 1987
- Country
- MNMD United States
- EYPT United States
- Employees
- MNMD N/A
- EYPT N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- MNMD Health Care
- EYPT Industrials
- Exchange
- MNMD Nasdaq
- EYPT Nasdaq
- Market Cap
- MNMD 811.9M
- EYPT 741.0M
- IPO Year
- MNMD N/A
- EYPT 2005
- Fundamental
- Price
- MNMD $12.51
- EYPT $14.00
- Analyst Decision
- MNMD Strong Buy
- EYPT Strong Buy
- Analyst Count
- MNMD 6
- EYPT 6
- Target Price
- MNMD $26.50
- EYPT $25.83
- AVG Volume (30 Days)
- MNMD 1.8M
- EYPT 1.1M
- Earning Date
- MNMD 11-06-2025
- EYPT 11-06-2025
- Dividend Yield
- MNMD N/A
- EYPT N/A
- EPS Growth
- MNMD N/A
- EYPT N/A
- EPS
- MNMD N/A
- EYPT N/A
- Revenue
- MNMD N/A
- EYPT $51,898,000.00
- Revenue This Year
- MNMD N/A
- EYPT N/A
- Revenue Next Year
- MNMD N/A
- EYPT N/A
- P/E Ratio
- MNMD N/A
- EYPT N/A
- Revenue Growth
- MNMD N/A
- EYPT 2.99
- 52 Week Low
- MNMD $4.70
- EYPT $3.91
- 52 Week High
- MNMD $12.94
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- MNMD 66.16
- EYPT 58.77
- Support Level
- MNMD $11.81
- EYPT $13.00
- Resistance Level
- MNMD $12.94
- EYPT $14.04
- Average True Range (ATR)
- MNMD 0.86
- EYPT 0.93
- MACD
- MNMD 0.17
- EYPT -0.08
- Stochastic Oscillator
- MNMD 88.48
- EYPT 61.60
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.